Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer
Efrat T. Harel,
Penelope M. Drake,
Robyn M. Barfield,
Irene Lui,
Shauna Farr-Jones,
Laura Van’t Veer,
Zev J. Gartner,
Evan M. Green,
André Luiz Lourenço,
Yifan Cheng,
Byron C. Hann,
David Rabuka,
Charles S. Craik
Affiliations
Efrat T. Harel
Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158, USA
Penelope M. Drake
Catalent Biologics, West, Emeryville, CA 94608, USA
Robyn M. Barfield
Catalent Biologics, West, Emeryville, CA 94608, USA
Irene Lui
Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158, USA
Shauna Farr-Jones
Department of Anesthesia and Perioperative Care, University of California, San Francisco, CA 94110, USA
Laura Van’t Veer
Laboratory Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94158, USA
Zev J. Gartner
Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158, USA
Evan M. Green
Biophysics Graduate Program and Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94158, USA
André Luiz Lourenço
Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158, USA
Yifan Cheng
Howard Hughes Medical Institute, University of California San Francisco, and Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94158, USA
Byron C. Hann
Preclinical Therapeutics Core, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94158, USA
David Rabuka
Catalent Biologics, West, Emeryville, CA 94608, USA
Charles S. Craik
Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158, USA
A promising molecular target for aggressive cancers is the urokinase receptor (uPAR). A fully human, recombinant antibody that binds uPAR to form a stable complex that blocks uPA-uPAR interactions (2G10) and is internalized primarily through endocytosis showed efficacy in a mouse xenograft model of highly aggressive, triple negative breast cancer (TNBC). Antibody-drug conjugates (ADCs) of 2G10 were designed and produced bearing tubulin inhibitor payloads ligated through seven different linkers. Aldehyde tag technology was employed for linking, and either one or two tags were inserted into the antibody heavy chain, to produce site-specifically conjugated ADCs with drug-to-antibody ratios of either two or four. Both cleavable and non-cleavable linkers were combined with two different antimitotic toxins—MMAE (monomethylauristatin E) and maytansine. Nine different 2G10 ADCs were produced and tested for their ability to target uPAR in cell-based assays and a mouse model. The anti-uPAR ADC that resulted in tumor regression comprised an MMAE payload with a cathepsin B cleavable linker, 2G10-RED-244-MMAE. This work demonstrates in vitro activity of the 2G10-RED-244-MMAE in TNBC cell lines and validates uPAR as a therapeutic target for TNBC.
